AnaptysBio在报告Q3收入丰厚,尽管内幕销售和负利润,却猛增到52周的高点。 AnaptysBio soared to a 52-week high after reporting strong Q3 earnings, despite insider sales and negative profits.

AnaptysBio（ANAB）在11月4日公布第三季度盈利强劲、每股收益0.52美元（远高于预期的106美元亏损）和7632万美元收入后，飙升至52周高点52.00美元，收于51.98万美元。 AnaptysBio (ANAB) surged to a 52-week high of $52.00, closing at $51.98, after reporting strong Q3 earnings on November 4 with $0.52 EPS—well above the expected loss of $1.06—and $76.32 million in revenue, far exceeding the $15.83 million estimate. 尽管利润指数为负值,但分析家仍然以55.40美元为目标,以股票回购授权和低股票波动为由,维持协商一致的“机动购买”评级。 Despite negative profitability metrics, analysts maintain a consensus "Moderate Buy" rating with a $55.40 target, citing a share repurchase authorization and low stock volatility. 12月内部销售减少了50%以上的所有权,但该公司继续推进抗体免疫和炎症治疗。 Insider sales in December reduced ownership by over 50%, but the company continues advancing antibody therapies for immunology and inflammation.